Quick answer: latest quarter results, by ticker or company name

Reported Q: Q3 2025 Rev YoY: +6.1% EPS YoY: +110.5% Move: +2.20%

Integrated BioPharma Inc

INBP

$0.290 2.20%

Exchange OTC Sector Consumer Defensive Industry Packaged Foods

Q3 2025

Published: May 14, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for INBP

Reported

Report Date

May 14, 2025

Quarter Q3 2025

Revenue

13.95M

YoY: +6.1%

EPS

0.02

YoY: +110.5%

Market Move

+2.20%

Previous quarter: Q2 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $13.95M up 6.1% year-over-year
EPS of $0.02 increased by 110.5% from previous year
Gross margin of 11.1%
Net income of 611.00K
"" -

INBP

Company INBP

Period Q3 2025

Currency USD

Report Type Quarterly Earnings

Generated Mar 29, 2026

Swipe to view all report sections

Executive Summary

Integrated BioPharma Inc (INBP) reported QQ3 2025 results with a modest top-line expansion and meaningful improvement in profitability and cash generation despite a small-scale operation. Revenue totaled $13.95 million, up 6.09% year-over-year and 10.57% quarter-over-quarter, while gross profit reached $1.55 million for a gross margin of 11.12%. EBITDA stood at $1.043 million and operating income at $0.739 million, yielding an operating margin of 5.30% and a net income of $0.611 million (EPS: $0.02). The quarter benefited from favorable cost control and mix shift, helping EBITDA and net income expand meaningfully versus prior periods (YoY EBITDA margin 7.48%; net income margin 4.38%).

Key Performance Indicators

Revenue

Increasing

13.95M

QoQ: 10.57% | YoY: 6.09%

Gross Profit

Increasing

1.55M

11.12% margin

QoQ: 32.45% | YoY: 24.28%

Operating Income

Increasing

739.00K

QoQ: 265.84% | YoY: 108.17%

Net Income

Increasing

611.00K

QoQ: 426.72% | YoY: 114.39%

EPS

Increasing

0.02

QoQ: 426.32% | YoY: 110.53%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: $13.95M; YoY +6.09%; QoQ +10.57%
Gross Profit: $1.551M; Gross Margin 11.12%; YoY Gross Profit growth +24.28%; QoQ +32.45%
Operating Income: $0.739M; Margin 5.30%; YoY +108.17%; QoQ +265.84%
Net Income: $0.611M; Margin 4.38%; YoY +114.39%; QoQ +426.72%
EPS: $0.02 basic/diluted; YoY +110.53%; QoQ +426.32%
EBITDA: $1.043M; EBITDA Margin 7.48%
Cash Flow: Operating cash flow $0.616M; Capex $0.116M; Free cash flow $0.500M; Net change in cash +$0.50M; Cash at period end $2.961M
Liquidity & Balance Sheet: Current ratio 3.72; Quick ratio 1.70; Cash ratio 0.59; Inventory $10.077M; Net receivables $5.08M; Total assets $25.656M; Total liabilities $5.273M; Total equity $20.383M; Retained earnings negative at $(31.241)M; Net debt position is negative $(1.825)M (cash greater than debt).
Valuation: Price/Earnings ~4.22x; Price/Book ~0.51x; EV/ EBITDA ~11.5x; Price/FCF ~20.6x.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	13.95M	6.09%	10.57%
Gross Profit	1.55M	24.28%	32.45%
Operating Income	739.00K	108.17%	265.84%
Net Income	611.00K	114.39%	426.72%
EPS	0.02	110.53%	426.32%

Key Financial Ratios

Return on Assets

Weak

2.38%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

3.00%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

3.72

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Conservative

0.06

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Value

4.22x

P/E ratio suggests potential undervaluation or stable earnings

Price to Book

Undervalued

0.51x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q1 2026	0.00	0.00	+0.0%	View
Q3 2025	13.95	0.02	+6.1%	View
Q2 2025	12.61	0.00	+9.6%	View
Q1 2025	13.62	0.01	-45.5%	View
Q4 2024	12.75	0.01	-1.9%	View

INBP

Integrated BioPharma Inc

Q1 2026 Report

Integrated BioPharma Inc (INBP) QQ1 2026 Results: Modest Profitability with Robust Cash Generation in a Capex-Light, Low-Leverage Profile...

Read full report

INBP

Integrated BioPharma Inc

Q2 2025 Report

Integrated BioPharma Inc (INBP) QQ2 2025 Results: Modest Margin Leverage and Solid Liquidity in a Niche Packaged Foods/Nutraceuticals Franchise...

Read full report

INBP

Integrated BioPharma Inc

Q1 2025 Report

Integrated BioPharma Inc (INBP) QQ1 2025 Results – Modest Revenue Stabilization and Margin Expansion in a Niche Consumer Defensive/Nutraceutical Mar...

Read full report

INBP

Integrated BioPharma Inc

Q4 2024 Report

Integrated BioPharma Inc (INBP) QQ4 2024 Results: Modest Revenue with Margin Stabilization and Balance Sheet Resilience...

Read full report

Integrated BioPharma Inc (INBP) Q3 2025 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Historical Earnings Comparison

More INBP Quarterly Reports

INBP

INBP

INBP

INBP

Q3 2025 Reports in Consumer Defensive Sector

Related Financial Data

Sector Analysis: Consumer Defensive

INBP Full Profile

INBP Financial Statements

Earnings Calendar